Johnson & Johnson to invest $1B-plus in Pennsylvania cell-therapy plant

Johnson & Johnson will invest more than $1 billion to build a next-generation cell-therapy manufacturing facility on its Janssen Biotech campus in Lower Gwynedd Township, near Ambler in Montgomery County, Pennsylvania, the company said in a Feb. 18 press release. The project, the company said, will create more than 4,000 construction jobs and about 500 permanent biomanufacturing positions and is part of a broader $55 billion U.S. investment program in manufacturing, research and development and technology through early 2029.

Johnson & Johnson framed the site as a strategic move to expand domestic capacity for its portfolio of advanced medicines for cancer, immune-mediated and neurological diseases, noting the facility will employ "cutting‑edge cell therapy technologies" to speed delivery of transformational treatments. The company said the investment will bolster its roughly $10 billion annual economic footprint in Pennsylvania, where it operates ten facilities totaling more than two million square feet of manufacturing, research, distribution and office space.

The announcement was highlighted by state officials, including Governor Josh Shapiro, underscoring competition among states for biopharma investment. U.S. Senator Dave McCormick praised the decision, saying, "Pennsylvania leads in life sciences and advanced manufacturing because we consistently deliver what companies like Johnson & Johnson need to succeed: a skilled workforce, premier research institutions, and proven manufacturing strength. This $1 billion-plus investment in a new Lower Gwynedd facility is a testament to that leadership and will produce life-changing treatments for patients, along with new and good jobs for our Commonwealth."

The Montgomery County project reinforces a recent surge of large-scale pharmaceutical commitments to Pennsylvania. It follows Eli Lilly's roughly $3.5 billion manufacturing pledge in Lehigh Valley earlier this year; together the deals bring private-sector commitments in the state to more than $4.5 billion in early 2026, signaling growing regional concentration in advanced therapies manufacturing.

The move also fits into a wider industry trend to reshore or expand U.S. production capacity. The federal government imposed a 100 percent tariff on branded drugs in October, though it specified the duty would apply only to producers that had not already broken ground on U.S. manufacturing plants. Johnson & Johnson has said this investment supports plans to "manufacture the vast majority of its advanced medicines in the U.S. to meet the needs of patients in the U.S."

Clinical pipeline context is modest: Johnson & Johnson currently has one approved cell therapy, Carvykti, for adults with certain types of multiple myeloma; the company did not specify which products, if any, will be made at the new site. The press release includes a site rendering and multimedia assets for the project, but it did not disclose a construction timeline, groundbreaking date or planned start of production.

For markets and policy watchers, the announcement matters on several fronts. It signals continued private capital flowing into U.S. advanced-therapies manufacturing, strengthens Pennsylvania's position in a high-value sector, and could influence state and local negotiations over workforce development and incentives. Key unanswered questions remain: exact capital phasing, whether state or local tax incentives were offered, the plant's production capacity and technology specifics, and the timetable for hiring the 500 permanent roles. Company materials name the asset and confirm corporate intent; detailed operational plans have not yet been released.